DexCom (XSWX:DXCM) Current Accrued Expense: CHF1,441 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:DXCM DexCom Inc XSWX:DXCM
95 GF Score
Price CHF70.36
GF Value CHF81.20
! 5 Warning Signs
View Full Analysis

What is DexCom Current Accrued Expense?

DexCom XSWX:DXCM +4.19% 95 Current Accrued Expense is CHF1,441 Mil as of Jun. 2026. GuruFocus rates XSWX:DXCM with a GF Score™ of 95/100 and a GF Value™ of CHF81.20. The stock has 5 warning signs investors should review.

DexCom's Current Accrued Expense for the quarter that ended in Jun. 2026 was CHF1,441 Mil.

DexCom's quarterly Current Accrued Expense increased from Dec. 2025 (CHF1,338 Mil) to Mar. 2026 (CHF1,339 Mil) and increased from Mar. 2026 (CHF1,339 Mil) to Jun. 2026 (CHF1,441 Mil).

DexCom's annual Current Accrued Expense increased from Dec. 2023 (CHF989 Mil) to Dec. 2024 (CHF1,118 Mil) and increased from Dec. 2024 (CHF1,118 Mil) to Dec. 2025 (CHF1,338 Mil).

DexCom Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for DexCom's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Current Accrued Expense Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 386.64 657.43 988.99 1,117.53 1,337.52

DexCom Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,218.34 1,253.46 1,337.52 1,339.12 1,440.82
XSWX:DXCM
95GF Score
DexCom Inc XSWX:DXCM
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of CHF1,441 Mil mean?
DexCom (XSWX:DXCM) has a Current Accrued Expense of CHF1,441 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on DexCom and its competitors.
Is DexCom's Current Accrued Expense too high?
DexCom's current Current Accrued Expense is CHF1,441 Mil. Overall, DexCom has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's Current Accrued Expense compare to GEHC and STE?
DexCom's Current Accrued Expense of CHF1,441 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on DexCom and its competitors. DexCom's current Current Accrued Expense is CHF1,441 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current Current Accrued Expense of CHF1,441 Mil. The stock's GF Value™ is CHF81.20, compared to a current price of CHF70.36 — trading 13.3% below its estimated fair value. The current Current Accrued Expense is CHF1,441 Mil. DexCom's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current Current Accrued Expense is CHF1,441 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (XSWX:DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of CHF70.36 is trading 13.3% below its estimated GF Value™ of CHF81.20.

Key valuation signals for XSWX:DXCM:

  • Current Accrued Expense: CHF1,441 Mil
  • GF Value™: CHF81.20 vs. price of CHF70.36 (13.3% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
95GF Score

Get the complete analysis for XSWX:DXCM

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF70.36
Price
CHF81.20
GF Value